High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
94.93B
+4.05%
1.483
-18.95%
97.86B
+2.55%
1.542
+41.49%
100.77B
+3.13%
0.977
-17.93%
Estimates Revision
The market is revising Upward the revenue expectations for CVS Health Corporation (CVS) for FY2025, with the revenue forecasts being adjusted by 0.16% over the past three months. During the same period, the stock price has changed by -7.34%.
Revenue Estimates for FY2025
Revise Upward
+0.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.96%
In Past 3 Month
Stock Price
Go Down
-7.34%
In Past 3 Month
21 Analyst Rating
0Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 78.25 USD with a low forecast of 70.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
3 Hold
0 Sell
Strong Buy
0Current: 60.870
Low
70.00
Averages
78.25
High
95.00
0Current: 60.870
Low
70.00
Averages
78.25
High
95.00
RBC Capital
Ben Hendrix
Buy
Maintains
$74 → $81
2025-05-05
Reason
RBC Capital
Ben Hendrix
Price Target
$74 → $81
2025-05-05
Maintains
Buy
Reason
RBC Capital raised the firm's price target on CVS Health to $81 from $74 and keeps an Outperform rating on the shares. The firm is updating its model after the company's Q1 results, which indicate solid early progress in recovering Medicare Advantage margins as medical cost trends show early signs of stabilization, the analyst tells investors in a research note. Alongside disciplined pricing, this could drive upside to consensus estimates in 2026 and beyond, RBC added.
UBS
Kevin Caliendo
Hold
Maintains
$67 → $71
2025-05-02
Reason
UBS
Kevin Caliendo
Price Target
$67 → $71
2025-05-02
Maintains
Hold
Reason
Barclays
Andrew Mok
Buy
Maintains
$73 → $82
2025-05-02
Reason
Barclays
Andrew Mok
Price Target
$73 → $82
2025-05-02
Maintains
Buy
Reason
Barclays raised the firm's price target on CVS Health to $82 from $73 and keeps an Overweight rating on the shares following the Q1 report.
Baird
Michael Ha
Hold
Maintains
$51 → $71
2025-04-15
Reason
Baird
Michael Ha
Price Target
$51 → $71
2025-04-15
Maintains
Hold
Reason
Baird raised the firm's price target on CVS Health to $71 from $51 and keeps a Neutral rating on the shares. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 "conservatism and cushion" given potential Part D and macro headwinds that may evolve later this year.
Truist Securities
David Macdonald
Strong Buy
Maintains
$76 → $82
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$76 → $82
2025-04-11
Maintains
Strong Buy
Reason
Truist raised the firm's price target on CVS Health to $82 from $76 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.
Mizuho
Ann Hynes
Buy
Maintains
$70 → $76
2025-04-09
Reason
Mizuho
Ann Hynes
Price Target
$70 → $76
2025-04-09
Maintains
Buy
Reason
Mizuho raised the firm's price target on CVS Health to $76 from $70 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital inpatient and outpatient trends during Q1. The survey suggests both inpatient and outpatient growth trends, while still elevated, appear to have peaked, the analyst tells investors in a research note. Mizuho views the survey as positive for managed care and clinical labs and neutral for hospitals.
See All Ratings
Valuation Metrics
The current forward P/E ratio for CVS Health Corp (CVS.N) is 10.45, compared to its 5-year average forward P/E of 10.01. For a more detailed relative valuation and DCF analysis to assess CVS Health Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
10.01
Current PE
10.45
Overvalued PE
11.40
Undervalued PE
8.62
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
9.08
Current EV/EBITDA
9.50
Overvalued EV/EBITDA
9.95
Undervalued EV/EBITDA
8.21
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
0.31
Current PS
0.22
Overvalued PS
0.39
Undervalued PS
0.23
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 50792.98% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 50792.98% over the last month.
Sold
Bought
CVS News & Events
Events Timeline
(ET)
2025-05-13
06:22:08
Trump's drug-price crackdown may lead to minor concessions, WSJ reports
2025-05-12 (ET)
2025-05-12
10:59:57
White House publishes Trump executive order aimed at lowering drug prices
2025-05-12
10:28:47
Trump says will 'cut out middlemen' to reduce drug prices
Sign Up For More Events
Sign Up For More Events
News
Preview
4.5
02:00 AMNASDAQ.COMDovish CPI Report and Strength in Chip Makers Boosts Stocks
Preview
8.0
00:44 AMBenzingaTrump Again Promises Lower Drug Prices By 'Cutting Out Middlemen' Like UnitedHealth, CVS: Will It Work This Time?
Preview
8.0
05-13BenzingaCVS Health, Cigna Stocks Dip Tuesday: What's Going On?
Sign Up For More News
People Also Watch
FAQ
What is CVS Health Corp (CVS) stock price today?
What is CVS Health Corp (CVS)'s business?
What is the price predicton of CVS Stock?
What is CVS Health Corp (CVS)'s revenue for the last quarter?
What is CVS Health Corp (CVS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CVS Health Corp (CVS)'s fundamentals?
How many employees does CVS Health Corp (CVS). have?